Estimated impact and value of blood-based colorectal cancer screening at varied adherence compared with stool-based screening

References

• Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(19):1965–1977. doi: 10.1001/jama.2021.6238.
   PubMed Web of Science ®Google Scholar
• Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250–281. doi: 10.3322/caac.21457.
   PubMed Web of Science ®Google Scholar
• Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol. 2021;116(3):458–479. doi: 10.14309/ajg.0000000000001122.
   PubMed Web of Science ®Google Scholar
• Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–573. doi: 10.1002/cncr.24760.
   PubMed Web of Science ®Google Scholar
• Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369(12):1106–1114. doi: 10.1056/NEJMoa1300720.
   PubMed Web of Science ®Google Scholar
• Piscitello A, Saoud L, Fendrick AM, et al. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model. PLoS One. 2020;15(12):e0244431. doi: 10.1371/journal.pone.0244431.
   PubMed Web of Science ®Google Scholar
• D’Andrea E, Ahnen DJ, Sussman DA, et al. Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality. Cancer Med. 2020;9(2):824–836. doi: 10.1002/cam4.2735.
   PubMed Web of Science ®Google Scholar
• Fisher DA, Karlitz JJ, Jeyakumar S, et al. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population. J Med Econ. 2021;24(1):654–664. doi: 10.1080/13696998.2021.1922240.
   PubMed Web of Science ®Google Scholar
• Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med. 2016;164(7):456–463. doi: 10.7326/M15-0983.
   PubMed Web of Science ®Google Scholar
• Rastogi N, Xia Y, Inadomi JM, et al. Disparities in colorectal cancer screening in New York City: an analysis of the 2014 NYC Community Health Survey. Cancer Med. 2019;8(5):2572–2579. doi: 10.1002/cam4.2084.
   PubMed Web of Science ®Google Scholar
• Ylitalo KR, Camp BG, Umstattd Meyer MR, et al. Barriers and facilitators of colorectal cancer screening in a Federally Qualified Health Center (FQHC). J Am Board Fam Med. 2019;32(2):180–190. doi: 10.3122/jabfm.2019.02.180205.
   PubMed Web of Science ®Google Scholar
• Muthukrishnan M, Arnold LD, James AS. Patients’ self-reported barriers to Colon cancer screening in federally qualified health center settings. Prev Med Rep. 2019;15:100896. doi: 10.1016/j.pmedr.2019.100896.
   PubMedGoogle Scholar
• Miller-Wilson LA, Rutten LJF, Van Thomme J, et al. Cross-sectional adherence with the multi-target stool DNA test for colorectal cancer screening in a large, nationally insured cohort. Int J Colorectal Dis. 2021;36(11):2471–2480. doi: 10.1007/s00384-021-03956-0.
   PubMed Web of Science ®Google Scholar
• Adler A, Geiger S, Keil A, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014;14(1):183. doi: 10.1186/1471-230X-14-183.
   PubMedGoogle Scholar
• Liles EG, Coronado GD, Perrin N, et al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: a randomized trial. Cancer Treat Res Commun. 2017;10:27–31. doi: 10.1016/j.ctarc.2016.12.004.
   Google Scholar
• Liang PS, Zaman A, Kaminsky A, et al. Blood test increases colorectal cancer screening in persons who declined colonoscopy and fecal immunochemical test: a randomized controlled trial. Clin Gastroenterol Hepatol. 2023;21(11):2951–2957.e2.
   Web of Science ®Google Scholar
• Symonds EL, Hughes D, Flight I, et al. A randomised controlled trial testing provision of fecal and blood test options on participation for colorectal cancer screening. Cancer Prev Res (Phila). 2019;12(9):631–640. doi: 10.1158/1940-6207.CAPR-19-0089.
   PubMed Web of Science ®Google Scholar
• Young GP, Chen G, Wilson CJ, et al. “Rescue” of nonparticipants in colorectal cancer screening: a randomized controlled trial of three noninvasive test options. Cancer Prev Res (Phila). 2021;14(8):803–810. doi: 10.1158/1940-6207.CAPR-21-0080.
   PubMed Web of Science ®Google Scholar
• Shaukat A, Levin TR. Current and future colorectal cancer screening strategies. Nat Rev Gastroenterol Hepatol. 2022;19(8):521–531. doi: 10.1038/s41575-022-00612-y.
   PubMed Web of Science ®Google Scholar
• Ladabaum U, Mannalithara A, Weng Y, et al. Comparative effectiveness and cost-effectiveness of colorectal cancer screening with blood-based biomarkers (liquid biopsy) vs fecal tests or colonoscopy. Gastroenterology. 2024. doi: 10.1053/j.gastro.2024.03.011.
   Google Scholar
• van den Puttelaar R, Nascimento de Lima P, Knudsen AB, et al. Effectiveness and cost-effectiveness of colorectal cancer screening with a blood test that meets the Centers for Medicare & Medicaid services coverage decision. Gastroenterology. 2024. doi: 10.1053/j.gastro.2024.02.012.
   PubMedGoogle Scholar
• Fendrick AM, Vahdat V, Chen JV, et al. Comparison of simulated outcomes between stool- and blood-based colorectal cancer screening tests. Popul Health Manag. 2023;26(4):239–245. doi: 10.1089/pop.2023.0037.
   PubMed Web of Science ®Google Scholar
• Knudsen AB, Rutter CM, Peterse EFP, et al. Colorectal cancer screening: an updated decision analysis for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality; 2021 [cited 2023 Jul 12]. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/document/final-modeling-report/colorectal-cancer-screening
   Google Scholar
• Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287–1297. doi: 10.1056/NEJMoa1311194.
   PubMed Web of Science ®Google Scholar
• Chung DC, Gray DM, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 2024;390(11):973–983. doi: 10.1056/NEJMoa2304714.
   PubMedGoogle Scholar
• National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) program. National Cancer Institute; 2021 [cited 2023 Jul 18]. Available from: www.seer.cancer.gov
   Google Scholar
• Vahdat V, Alagoz O, Chen JV, et al. Calibration and validation of the colorectal cancer and adenoma incidence and mortality (CRC-AIM) microsimulation model using deep neural networks. Med Decis Making. 2023;43(6):719–736. doi: 10.1177/0272989X231184175.
   PubMed Web of Science ®Google Scholar
• Cooper GS, Grimes A, Werner J, et al. Barriers to follow-up colonoscopy after positive FIT or multitarget stool DNA testing. J Am Board Fam Med. 2021;34(1):61–69. doi: 10.3122/jabfm.2021.01.200345.
   PubMed Web of Science ®Google Scholar
• Clinical laboratory fee schedule. Baltimore (MD): Centers for Medicare & Medicaid Services; 2022 [cited 2023 Jun 23]. Available from: https://www.cms.gov/medicare/medicare-fee-for-service-payment/clinicallabfeesched
   Google Scholar
• Guardant Health Second Quarter 2022 Financial Results Call. Guardant Health; 2022 [cited 2023 Jun 23]. Available from: https://investors.guardanthealth.com/events-and-presentations/events/event-details/2022/Guardant-Health-Q2-2022-Earnings-Call/default.aspx
   Google Scholar
• Shepard DS. Cost-effectiveness in health and medicine. By M.R. Gold, J.E Siegel, L.B. Russell, and M.C. Weinstein (eds). New York: Oxford University Press, 1996. J Ment Health Policy Econ. 1999;2(2):91–92.
   Google Scholar
• Coronado GD, Jenkins CL, Shuster E, et al. Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence. Gut. 2024;73(4):622–628. doi: 10.1136/gutjnl-2023-330980.
   PubMed Web of Science ®Google Scholar
• Pickhardt PJ, Graffy PM, Weigman B, et al. Diagnostic performance of multitarget stool DNA and CT colonography for noninvasive colorectal cancer screening. Radiology. 2020;297(1):120–129. doi: 10.1148/radiol.2020201018.
   PubMed Web of Science ®Google Scholar
• Rex DK, Ladabaum U, Anderson JC, et al. Does screening colonoscopy have a future in the United States?. Clin Gastroenterol Hepatol. 2023;21(12):3005–3010. doi: 10.1016/j.cgh.2023.05.034.
   PubMed Web of Science ®Google Scholar
• Lieberman DA, Shaukat A, May FP, et al. Commentary: liquid biopsy for average-risk colorectal cancer screening. Clin Gastroenterol Hepatol. 2024. doi: 10.1016/j.cgh.2024.01.034.
   PubMedGoogle Scholar
• Kisiel J, Lieberman D, Fendrick A, et al. Estimated adenoma sensitivity threshold needed for blood-based colorectal cancer screening tests to be as effective as stool-based screening tests. Gastroenterology. 2023;164(6):S-983. doi: 10.1016/S0016-5085(23)03271-7.
   Web of Science ®Google Scholar
• Hanna M, Dey N, Grady WM. Emerging tests for noninvasive colorectal cancer screening. Clin Gastroenterol Hepatol. 2023;21(3):604–616. doi: 10.1016/j.cgh.2022.12.008.
   PubMed Web of Science ®Google Scholar
• Imperiale TF, Porter K, Zella J, et al. Next-Generation multitarget stool DNA test for colorectal cancer screening. N Engl J Med. 2024;390(11):984–993. doi: 10.1056/NEJMoa2310336.
   PubMedGoogle Scholar
• Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(23):2564–2575. doi: 10.1001/jama.2016.5989.
   PubMed Web of Science ®Google Scholar